• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 3. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 4. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroidal glycosides Steroidal saponins
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroidal saponins

Introduction to Lirioprolioside B (CAS No. 182284-68-0)

Lirioprolioside B, a naturally occurring compound with the chemical formula CAS No. 182284-68-0, has garnered significant attention in the field of pharmaceutical research and natural product chemistry. This glycoside, derived from the plant Liriope spicata, belongs to the flavonoid family and exhibits a unique structural configuration that has piqued the interest of scientists worldwide.

The structural complexity of Lirioprolioside B makes it a subject of extensive study in medicinal chemistry. Its molecular framework consists of a flavone core substituted with various sugar moieties, which contribute to its diverse biological activities. Recent advancements in spectroscopic techniques and computational chemistry have enabled researchers to elucidate its precise structure, revealing insights into its potential pharmacological properties.

One of the most compelling aspects of Lirioprolioside B is its demonstrated potential in preclinical studies. Research indicates that this compound possesses anti-inflammatory, antioxidant, and anticancer properties, making it a promising candidate for therapeutic applications. Specifically, studies have shown that Lirioprolioside B can modulate key signaling pathways involved in cancer progression, such as the PI3K/Akt and MAPK pathways. These findings have opened new avenues for the development of novel anticancer agents.

In addition to its anticancer potential, Lirioprolioside B has shown remarkable efficacy in combating oxidative stress and inflammation. Oxidative stress is a hallmark of numerous chronic diseases, including neurodegenerative disorders like Alzheimer's and Parkinson's disease. Preliminary research suggests that Lirioprolioside B can scavenge reactive oxygen species (ROS) and inhibit the activation of pro-inflammatory cytokines, thereby protecting against cellular damage.

The biosynthesis of Lirioprolioside B is another area of intense investigation. Understanding the metabolic pathways responsible for its production in Liriope spicata could provide valuable insights into how this compound is synthesized and potentially how its bioavailability can be enhanced. Advances in metabolomics and genetic engineering have allowed researchers to identify key enzymes and genes involved in its biosynthesis, paving the way for biotechnological approaches to optimize its production.

From a synthetic chemistry perspective, the structural features of Lirioprolioside B present both challenges and opportunities for total synthesis. The presence of multiple stereocenters and glycosidic linkages requires sophisticated synthetic strategies to achieve high yields and enantiopurity. However, recent breakthroughs in asymmetric synthesis have made it possible to construct complex natural products like Lirioprolioside B with increasing efficiency, bringing us closer to large-scale production.

The pharmacokinetic profile of Lirioprolioside B is also a critical factor in determining its therapeutic potential. Studies using advanced analytical techniques such as liquid chromatography-mass spectrometry (LC-MS) have provided valuable data on its absorption, distribution, metabolism, and excretion (ADME) properties. These insights are crucial for optimizing drug delivery systems and ensuring that Lirioprolioside B reaches its target sites effectively.

Future research directions for Lirioprolioside B include exploring its mechanism of action at a molecular level and identifying potential off-target effects that could influence its safety profile. Collaborative efforts between academia and industry are essential to translate preclinical findings into clinical trials, where its efficacy and safety can be rigorously evaluated in human populations.

In conclusion, Lirioprolioside B (CAS No. 182284-68-0) represents a fascinating natural product with significant therapeutic potential. Its unique chemical structure, coupled with promising biological activities, positions it as a valuable asset in the quest for novel pharmaceuticals. As research continues to uncover new aspects of this compound's properties and applications, it is likely to play an increasingly important role in drug discovery and development.

• 168009-87-8(b-D-Glucopyranoside, (1b,3b,25S)-3-hydroxyspirost-5-en-1-yl O-b-D-glucopyranosyl-(1(R)3)-O-6-deoxy-a-L-mannopyranosyl-(1(R)2)-O-[b-D-xylopyranosyl-(1(R)3)]-, 6-acetate (9CI))
• 1220707-33-4(2''-O-Acetylsprengerinin C)
• 65604-79-7(Ophiopogonin B')
• 1309084-25-0((25R)-26-O-beta-D-glucopyranosyl-5alpha-furostan-3beta,22alpha,26-triol 3-O-beta-D-glucopyranosyl-(1->6)-O-beta-D-glucopyranoside)
• 1418183-23-9(diosgenin 3-O-[4-O-acetyl-alpha-L-rhamnopyranosyl(1?2)][beta-D-xylopyranosyl(1?4)]-beta-D-glucopyranoside)
• 190781-46-5(b-D-Galactopyranoside, (1b,3b,12b,23S,24S,25R)-1-[(O-4-O-acetyl-6-deoxy-a-L-mannopyranosyl-(1®2)-O-[b-D-xylopyranosyl-(1®3)]-b-D-glucopyranosyl)oxy]-3,12,23-trihydroxyspirost-5-en-24-yl6-deoxy- (9CI))
• 130431-11-7((25S)-ruscogenin 1-O-2)>3)>-beta-D-fucopyranoside)
• 1486510-50-2(25(S)-ruscogenin 1-O-alpha-L-rhamnopyranosyl-(1?2)-[beta-D-xylopyranosyl-(1?3)]-4-O-acetyl-beta-D-fucopyranoside)
• 11054-24-3(b-D-Galactopyranoside, (1b,3b,25R)-3-hydroxyspirost-5-en-1-yl2-O-(3-O-acetyl-6-deoxy-a-L-mannopyranosyl)-6-deoxy-)
• 214056-88-9((1beta,3beta,23S,25R)-23-(beta-D-glucopyranosyloxy)-3-hydroxyspirost-5-en-1-yl beta-D-glucopyranosyl-(1->3)-6-deoxy-alpha-L-mannopyranosyl-(1->2)-3,4,6-tri-O-acetyl-beta-D-galactopyranoside)